In the combination study , @ % of the patients in the dupilumab group , as compared with @ % of those who received topical glucocorticoids with placebo injection , met the criterion for EASI-@ ( P = @ ) , despite the fact that patients who received dupilumab plus glucocorticoids used less than half the amount of topical glucocorticoids used by those who received placebo plus the topical medication ( P = @ ) .